LGND vs RPRX
LGND: Ligand Pharmaceuticals is a high-margin, asset-light biopharmaceutical firm that earns royalties and milestone payments from a diverse portfolio of licensed drug development programs and its proprietary Captisol formulation technology. RPRX: Royalty Pharma is the leading acquirer of biopharmaceutical royalties, providing capital to fund medical innovation in exchange for long-term revenue streams from successful therapeutic products.
Side-by-side fundamentals
| Metric | LGND | RPRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $295.00 | $56.21 | |
| Market cap | $5.9B | $21.8B | |
| P/E as of 2026-10-08 | 39.74 | 38.49 | RPRX lower |
| Net margin FY2025, SEC XBRL | +46.4% | +32.4% | LGND higher |
| Operating margin FY2025, SEC XBRL | +15.3% | +65.6% | RPRX higher |
| ROE FY2025, SEC XBRL | +12.2% | +7.9% | LGND higher |
| ROA FY2025, SEC XBRL | +8.0% | +3.9% | LGND higher |
| Debt / equity as of 2026-09-03 | 0.45 | 1.31 | LGND lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +10.0% | |
| Revenue CAGR (3y) SEC XBRL | +11.0% | +2.1% | LGND higher |
| Dividend yield as of 2026-09-02 | n/a | +1.6% | |
| Dividend streak (yrs) SEC XBRL | 1 | 5 | RPRX higher |
| Beta as of 2026-09-03 | 0.96 | 0.27 | |
| 1-year return as of 2026-10-08 close | +59.9% | +56.1% | LGND higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.